Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials

Pankaj Aggarwal, Mazen Noureddin, Stephen Harrison, Sophie Jeannin, Naim Alkhouri

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Introduction: Patients with nonalcoholic steatohepatitis (NASH)-associated cirrhosis have the highest rates of major adverse liver outcomes (MALO) within the fatty liver disease spectrum and therefore have the highest unmet need for effective therapeutic agents. Several drugs are being tested for patients with NASH cirrhosis with different mechanisms of action and endpoints. Areas covered: This article summarizes the available data on the natural history of NASH cirrhosis and the rates of developing MALO. We provide examples of ongoing clinical trials for NASH cirrhosis including the study design and endpoints. We then discuss the FDA-guidance on acceptable endpoints for NASH cirrhosis trials that will lead to approval. Expert opinion: Metabolic and antifibrotic drugs are currently in phase 2b trials for NASH cirrhosis with outcomes ranging from histologic improvement on liver biopsy to the development of varices or MALO. We provide the readers with pragmatic advice on trial design for phase 2B and 3 NASH cirrhosis trials. The data presented in the article justify further development and investigation of therapeutic agents for the treatment of NASH cirrhosis.

Original languageEnglish (US)
Pages (from-to)163-172
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume31
Issue number2
DOIs
StatePublished - 2022

Keywords

  • Nonalcoholic steatohepatitis (NASH)
  • aldafermin
  • cirrhosis
  • clinical trials
  • clinical trials
  • natural history
  • obeticholic acid
  • resmetirom

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials'. Together they form a unique fingerprint.

Cite this